Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 33 of 33 matching drugs for ABCC1 — including drugs targeting any of its 52 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
pharmacological study, romidepsin ABCC1 Direct 2
romidepsin ABCC1 Direct 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule ABCC1 Direct 1
romidepsin, laboratory biomarker analysis ABCC1 Direct 1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMO SSL via SMO 3
pembrolizumab, sonidegib SMO SSL via SMO 2
alisertib AURKA SSL via AURKA 1
alisertib, gemcitabine AURKA SSL via AURKA 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SMO SSL via SMO 1
biopsy, biospecimen collection, echocardiography, radionuclide imaging, vismodegib SMO SSL via SMO 1
diagnostic laboratory biomarker analysis, erlotinib hydrochloride, gemcitabine hydrochloride, vismodegib SMO SSL via SMO 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) AURKA SSL via AURKA 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) PIK3R1 SSL via PIK3R1 1
enzastaurin, lomustine AURKA SSL via AURKA 1
enzastaurin, lomustine PIK3R1 SSL via PIK3R1 1
enzastaurin, temozolomide, radiation therapy AURKA SSL via AURKA 1
enzastaurin, temozolomide, radiation therapy PIK3R1 SSL via PIK3R1 1
gemcitabine hydrochloride, hydrocortisone/placebo, vismodegib SMO SSL via SMO 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim SMO SSL via SMO 1
hyperfractionated radiation therapy, stereotactic radiosurgery, alisertib, quality-of-life assessment AURKA SSL via AURKA 1
vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose f 18 SMO SSL via SMO 1
vismodegib, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study SMO SSL via SMO 1
amifampridine KCNQ4 SSL via KCNQ4 yes 0
amifampridine phosphate KCNQ4 SSL via KCNQ4 yes 0
dalfampridine KCNQ4 SSL via KCNQ4 yes 0
ezogabine KCNQ4 SSL via KCNQ4 yes 0
glasdegib SMO SSL via SMO yes 0
glasdegib maleate SMO SSL via SMO yes 0
guanidine KCNQ4 SSL via KCNQ4 yes 0
guanidine hydrochloride KCNQ4 SSL via KCNQ4 yes 0
sonidegib SMO SSL via SMO yes 0
sonidegib phosphate SMO SSL via SMO yes 0
vismodegib SMO SSL via SMO yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.